Tyra Biosciences, Inc. Common Stock
TYRATyra Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetically-defined cancers. Utilizing precision medicine approaches, Tyra aims to identify and develop novel treatments that address specific genetic alterations driving cancer growth. The company is engaged in research and development efforts to bring innovative cancer therapies to market.
Company News
Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinic...
Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expec...
BALVERSA (erdafitinib), a targeted therapy for FGFR-altered urothelial carcinoma, has strong market potential as precision oncology gains emphasis. Its uptake is expected to increase, especially if expanded to earlier treatment lines or additional FGFR-driven tumors.
The advanced urothelial carcinoma market is witnessing significant growth, driven by an aging population and the rising prevalence of metastatic cases. Advances in immunotherapy and targeted treatments are transforming the treatment landscape, with over 20 key companies developing new therapies.
Tyra Biosciences, a leading biotechnology company, has reached a new 52-week high of $21.67, reflecting its robust performance and investor confidence. The company has made progress in the development of its therapeutic candidate TYRA-300 for hypochondroplasia, with positive preclinical data presented at a research conference.
